EPCAM and colonic neoplasm: The mid-1990s brought about large clinical phase studies utilizing the monoclonal anti-EpCAM antibody Edrecolomab [62,63], which resulted in Food and Drug Administration (FDA) approval and market introduction of Panorex for the treatment of metastasized colon cancer.